Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
X Xu, KL Poulsen, L Wu, S Liu, T Miyata… - Signal transduction and …, 2022 - nature.com
Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading
cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive …
cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive …
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease
worldwide. With no Food and Drug Administration approved drugs, current treatment options …
worldwide. With no Food and Drug Administration approved drugs, current treatment options …
Current and potential therapies targeting inflammation in NASH
S Albhaisi, M Noureddin - Frontiers in endocrinology, 2021 - frontiersin.org
Nonalcoholic steatohepatitis (NASH) is the advanced form of nonalcoholic fatty liver disease
(NAFLD). It is characterized by hepatic steatosis, inflammation, hepatocellular injury, and …
(NAFLD). It is characterized by hepatic steatosis, inflammation, hepatocellular injury, and …
The race to bash NASH: emerging targets and drug development in a complex liver disease
FA Romero, CT Jones, Y Xu, M Fenaux… - Journal of medicinal …, 2020 - ACS Publications
Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease
(NAFLD) characterized by liver steatosis, inflammation, and hepatocellular damage. NASH …
(NAFLD) characterized by liver steatosis, inflammation, and hepatocellular damage. NASH …
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem worldwide and an
important risk factor for both hepatic and cardiometabolic mortality. The rapidly increasing …
important risk factor for both hepatic and cardiometabolic mortality. The rapidly increasing …
Current options and future directions for NAFLD and NASH treatment
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease
worldwide, with a broad spectrum ranging from simple steatosis to advanced stage of …
worldwide, with a broad spectrum ranging from simple steatosis to advanced stage of …
Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH)
A Takaki, D Kawai, K Yamamoto - International journal of molecular …, 2014 - mdpi.com
Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease
(NAFLD), in which most patients exhibit non-progressive, non-alcoholic fatty liver (NAFL) …
(NAFLD), in which most patients exhibit non-progressive, non-alcoholic fatty liver (NAFL) …
Insights into the epidemiology, pathogenesis, and therapeutics of nonalcoholic fatty liver diseases
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease which affects≈
25% of the adult population worldwide, placing a tremendous burden on human health. The …
25% of the adult population worldwide, placing a tremendous burden on human health. The …
Pathogenesis of nonalcoholic steatohepatitis and hormone-based therapeutic approaches
KH Kim, MS Lee - Frontiers in endocrinology, 2018 - frontiersin.org
Non-alcoholic fatty liver disease (NAFLD) is an emerging global health problem and a
potential risk factor for type 2 diabetes, cardiovascular disease, and chronic kidney disease …
potential risk factor for type 2 diabetes, cardiovascular disease, and chronic kidney disease …
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Successful development of treatments for non-alcoholic fatty liver disease and its
progressive form, non-alcoholic steatohepatitis (NASH), has been challenging. Because …
progressive form, non-alcoholic steatohepatitis (NASH), has been challenging. Because …